2 completed, 2 recruiting. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow KLU156: new trials by email Literature Review of KLU156 trials Research Report on KLU156
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-02-12 | 2026-10-15 |
| Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria KLU156, Coartem - Uncomplicated Plasmodium Falciparum Malaria | Phase 3 | Completed | Novartis Pharmaceuticals | 1720 | 2024-03-07 | 2026-01-27 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2024-01-23 | 2026-05-07 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria INE963, KAE609 (Cipargamin), SoC (Coartem) - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | Novartis Pharmaceuticals | 327 | 2024-01-23 | 2025-07-30 |
Malaria, Falciparum (4) · Malaria (2)
Côte d’Ivoire (4) · Gabon (4) · Kenya (4) · Burkina Faso (3) · Ghana (3) · Uganda (3) · Rwanda (2) · Democratic Republic of the Congo (1) · Mali (1) · Niger (1) · Tanzania (1) · Zambia (1)